Come up with a name for your new list and we'll add to it:
Viralytics raised a round of funding on February 21, 2018. Investors include
Merck & Co..
Viralytics is focused on the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells.…